NASDAQ:CPXX - Celator Pharmaceuticals Stock Price, Price Target & More

$30.24 0.00 (0.00 %)
(As of 04/20/2018 02:57 AM ET)
Previous Close$30.24
Today's Range$30.24 - $30.24
52-Week Range$1.12 - $30.36
Volume1,000 shs
Average Volume2.62 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals logoCelator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Receive CPXX News and Ratings via Email

Sign-up to receive the latest news and ratings for CPXX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:CPXX
CUSIPN/A
WebN/A
Phone+1-609-2430123

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-75.03%
Return on Assets-46.70%

Miscellaneous

EmployeesN/A
Outstanding Shares42,870,000

How to Become a New Pot Stock Millionaire

Celator Pharmaceuticals (NASDAQ:CPXX) Frequently Asked Questions

What is Celator Pharmaceuticals' stock symbol?

Celator Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPXX."

How were Celator Pharmaceuticals' earnings last quarter?

Celator Pharmaceuticals Inc (NASDAQ:CPXX) posted its quarterly earnings results on Tuesday, May, 10th. The company reported ($0.16) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. View Celator Pharmaceuticals' Earnings History.

Who are some of Celator Pharmaceuticals' key competitors?

Has Celator Pharmaceuticals been receiving favorable news coverage?

News articles about CPXX stock have trended positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Celator Pharmaceuticals earned a news impact score of 0.36 on Accern's scale. They also assigned news stories about the company an impact score of 48.19 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

How do I buy shares of Celator Pharmaceuticals?

Shares of CPXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celator Pharmaceuticals' stock price today?

One share of CPXX stock can currently be purchased for approximately $30.24.

How can I contact Celator Pharmaceuticals?

Celator Pharmaceuticals' mailing address is 303b College Rd E, PRINCETON, NJ 08540-6608, United States. The company can be reached via phone at +1-609-2430123.


MarketBeat Community Rating for Celator Pharmaceuticals (CPXX)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  109 (Vote Outperform)
Underperform Votes:  54 (Vote Underperform)
Total Votes:  163
MarketBeat's community ratings are surveys of what our community members think about Celator Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPXX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPXX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celator Pharmaceuticals (NASDAQ:CPXX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Celator Pharmaceuticals (NASDAQ:CPXX) Consensus Price Target History

Price Target History for Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals (NASDAQ:CPXX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2016Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
6/1/2016Stifel NicolausDowngradeBuy -> HoldN/AView Rating Details
5/31/2016Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
5/31/2016Roth CapitalDowngradeBuy -> Neutral$30.25 -> $26.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Celator Pharmaceuticals (NASDAQ:CPXX) Earnings History and Estimates Chart

Earnings by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals (NASDAQ CPXX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q116($0.15)($0.16)ViewListenView Earnings Details
3/21/2016Q4($0.12)($0.13)ViewN/AView Earnings Details
11/12/2015Q315($0.16)($0.15)ViewListenView Earnings Details
8/11/2015Q215($0.14)($0.15)ViewListenView Earnings Details
5/7/2015Q1 2015($0.14)($0.14)ViewN/AView Earnings Details
3/17/2015Q4 2014($0.16)($0.07)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.21)($0.21)ViewN/AView Earnings Details
8/7/2014Q2 2014($0.20)($0.18)ViewN/AView Earnings Details
5/12/2014Q1 2014($0.24)($0.16)ViewN/AView Earnings Details
3/24/2014Q4 13($0.15)($0.13)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.20)($0.14)ViewN/AView Earnings Details
8/14/2013Q2 2013($0.20)($0.18)ViewN/AView Earnings Details
5/15/2013Q1 2013($0.20)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Celator Pharmaceuticals (NASDAQ:CPXX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Celator Pharmaceuticals (NASDAQ CPXX) Insider Trading and Institutional Ownership History

Insider Trading History for Celator Pharmaceuticals (NASDAQ:CPXX)
Insider Trading History for Celator Pharmaceuticals (NASDAQ:CPXX)

Celator Pharmaceuticals (NASDAQ CPXX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/3/2015Scott D MorensteinDirectorBuy5,000$1.87$9,350.00View SEC Filing  
10/6/2015Scott Thomas JacksonCEOBuy14,450$1.74$25,143.0050,043View SEC Filing  
10/5/2015Fred M PowellCFOBuy13,700$1.78$24,386.0031,458View SEC Filing  
10/1/2015Life Sciences Gp Ll Valence IIinsiderBuy12,200$1.64$20,008.00171,986View SEC Filing  
11/18/2014Fred M PowellCFOBuy6,000$2.20$13,200.00View SEC Filing  
11/18/2014Michael R DoughertyDirectorBuy20,000$2.15$43,000.00View SEC Filing  
11/18/2014Scott Thomas JacksonCEOBuy10,000$2.20$22,000.00View SEC Filing  
5/15/2014Fred M PowellCFOBuy2,500$2.50$6,250.00View SEC Filing  
12/17/2013Fred M PowellCFOBuy2,500$3.50$8,750.00View SEC Filing  
12/17/2013Scott Thomas JacksonCEOBuy3,000$3.50$10,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celator Pharmaceuticals (NASDAQ CPXX) News Headlines

Source:
DateHeadline
Altum Is Launching Biotech Insider - Seeking AlphaAltum Is Launching Biotech Insider - Seeking Alpha
seekingalpha.com - March 14 at 10:42 AM
Seattle Genetics (SGEN) & Celator Pharmaceuticals (CPXX) Critical ComparisonSeattle Genetics (SGEN) & Celator Pharmaceuticals (CPXX) Critical Comparison
www.americanbankingnews.com - February 5 at 1:12 AM
Comparing Celator Pharmaceuticals (CPXX) & Cara Therapeutics (CARA)Comparing Celator Pharmaceuticals (CPXX) & Cara Therapeutics (CARA)
www.americanbankingnews.com - January 23 at 5:30 PM
Financial Analysis: Celator Pharmaceuticals (CPXX) versus Checkpoint Therapeutics (CKPT)Financial Analysis: Celator Pharmaceuticals (CPXX) versus Checkpoint Therapeutics (CKPT)
www.americanbankingnews.com - January 16 at 9:32 AM
Celator Pharmaceuticals (CPXX) & The Competition Head to Head ContrastCelator Pharmaceuticals (CPXX) & The Competition Head to Head Contrast
www.americanbankingnews.com - October 30 at 3:26 PM
Head to Head Analysis: Celator Pharmaceuticals (CPXX) & Genomic Health (GHDX)Head to Head Analysis: Celator Pharmaceuticals (CPXX) & Genomic Health (GHDX)
www.americanbankingnews.com - September 23 at 10:28 PM
Form 8-K Moleculin Biotech, Inc. For: Jun 29 - StreetInsider.com - StreetInsider.comForm 8-K Moleculin Biotech, Inc. For: Jun 29 - StreetInsider.com - StreetInsider.com
www.streetinsider.com - June 30 at 5:40 PM
Form 8-K Moleculin Biotech, Inc. For: May 23 - StreetInsider.comForm 8-K Moleculin Biotech, Inc. For: May 23 - StreetInsider.com
www.streetinsider.com - May 24 at 6:33 AM
Moleculin Biotech (MBRX) Issues Shareholder Update - StreetInsider.comMoleculin Biotech (MBRX) Issues Shareholder Update - StreetInsider.com
www.streetinsider.com - May 23 at 3:25 PM
Marinus Pharmaceuticals: A Discarded CNS Gem Ready To Shine ... - Seeking AlphaMarinus Pharmaceuticals: A Discarded CNS Gem Ready To Shine ... - Seeking Alpha
seekingalpha.com - May 9 at 8:07 AM
Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission ... - PR Newswire (press release)Jazz Pharmaceuticals Initiates Rolling NDA Submission for Vyxeos (CPX-351) Expects to Complete NDA Submission ... - PR Newswire (press release)
www.prnewswire.com - October 3 at 4:14 PM
With Impressive Data in Tow, Actinium Pharma An Overlooked ... - PR Newswire (press release)With Impressive Data in Tow, Actinium Pharma An Overlooked ... - PR Newswire (press release)
www.prnewswire.com - August 10 at 10:34 PM
CELATOR PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of AcquisiCELATOR PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisi
biz.yahoo.com - July 12 at 4:02 PM
Jazz Pharmaceuticals (JAZZ) Offers Results from Celator Pharma (CPXX) Tender Offer - StreetInsider.comJazz Pharmaceuticals (JAZZ) Offers Results from Celator Pharma (CPXX) Tender Offer - StreetInsider.com
www.streetinsider.com - July 12 at 8:40 AM

SEC Filings

Celator Pharmaceuticals (NASDAQ:CPXX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celator Pharmaceuticals (NASDAQ:CPXX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celator Pharmaceuticals (NASDAQ CPXX) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.